report rel in-lin sale ep outpac est
respect driven strength keytruda y/i anim health
ex-fx base strength confid achiev mid-
point sale guidanc rais sale forecast
driven higher anim health forecast break belsomra
insomnia expect keytruda oncolog drive meaning margin expans rel
current level rais out-year op margin vs prior boost
ep vs prior base improv outlook merck profit
rais po reiter buy
area focu call
takeaway truda us lung launch management updat us truda
two-third share new patient start elig metastat lung pt
share pt higher pre-aacr medic meet april expect substanti
uptak go forward management updat us sale deriv lung
cancer suggest sequenti sale increas vs total drug growth
q/q anim health spite strong y/i growth management reiter
commit keep busi rather divest/spin mgmt state rational
keep anim health merck portfolio relat synergi deriv pharma
anim health includ protein technolog access human catalogu
drug advanc anim believ unit fit strateg intent gross
margin expect vs compar prior guidanc slightli
lower y/i impact transient adempa mileston cyber-attack issu
drag vs dont view issu
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
price object po base blend averag risk-adjust
discount cash flow dcf target price-to-earnings multipl appli ep dcf
assum wacc termin growth rate believ dcf assumpt
reason given minim contribut new keytruda indic
yet valid late-stag clinic studi erod revenu base
januvia/janumet zepati neg termin growth target price-to-earnings
multipl base regress analysi histor us major pharma
forward price-to-earnings multipl three-year forward compound-annual-growth-rate non-gaap
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip price pressur
diabet franchis neg result late-stag clinic program
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
